2026-10-14T14:18:04Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33971695 2026-09-23T07:37:26Z category_19 portal_316 item_type_3 month_year_09_2026

Table 1_Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.docx Aadhila Abbas Manthiri (24147057) Leen Haj Saleh (24147060) Marrita Rabadi (25095139) Ayman Dalol (24501422) Rowan Mesilhy (25095142) Usra Elshaikh (16886009) Abdulrahman F. Al-Mashdali (17148316) Mohammed Abdulgayoom (14777791) Shehab F. Mohamed (17945561) Pharmacology ropeginterferon alfa-2b efficacy hematological response safety myeloproliferative neoplasms polycythemia vera essential thrombocythemia myelofibrosis Background<p>Ropeginterferon alfa-2b (ropegIFN-α2b or ropeginterferon) has emerged as a therapeutic option for patients with myeloproliferative neoplasms, particularly polycythemia vera (PV), with potential disease-modifying effects. This systematic review aimed to evaluate the efficacy and safety of ropeginterferon across clinical and real-world studies.</p>Methods<p>A systematic search of PubMed, Embase, and Web of Science was conducted to identify studies reporting clinical outcomes of ropeginterferon in patients with MPNs. An additional PubMed search was performed to capture recently published studies. Eligible studies were screened according to predefined inclusion criteria. Data on hematologic, molecular, clinical, and safety outcomes were extracted and narratively synthesized. A proportional meta-analysis was conducted for selected outcomes, including complete hematologic response (CHR), partial molecular response (PMR), and grade ≥3 cytopenias.</p>Results<p>A total of 18 studies involving 1,836 patients were included. Pooled analysis demonstrated that CHR rates increased over time, from 26% at 3 months to 59% at 12 months, with an overall pooled estimate of 56% (95% CI: 46%–66%). PMR was achieved in 37% of patients (95% CI: 20%–59%), although with substantial heterogeneity. Molecular responses were supported by consistent reductions in JAK2 allele burden across studies. Clinical outcomes showed improvements in spleen size and symptom burden in several cohorts. Ropeginterferon was generally well tolerated. The pooled proportion of grade ≥3 cytopenias was 3% (95% CI: 1%–10%), and severe hepatotoxicity was uncommon, typically occurring in ≤5% of patients. Most adverse events were low grade, with infrequent treatment discontinuations.</p>Conclusion<p>RopegIFN-α2b demonstrates favorable efficacy and safety profiles in patients with MPNs, especially in PV, with evidence of progressive hematologic and molecular responses over time. These findings support its role as a potentially disease-modifying therapy, although further standardized and long-term studies, focusing on ET and MF, are needed.</p>Systematic Review Registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD420261337306, identifier CRD420261337306.</p> 2026-09-23T07:37:26Z Dataset Dataset 10.3389/fphar.2026.1841557.s001 https://figshare.com/articles/dataset/Table_1_Efficacy_and_safety_of_ropeginterferon_in_myeloproliferative_neoplasms_a_systematic_review_and_meta-analysis_docx/33971695 CC BY 4.0